Por favor, use este identificador para citar o enlazar este ítem: http://www.repositorio.ufop.br/jspui/handle/123456789/12242
Título : The evaluation of valsartan biopharmaceutics properties.
Autor : Castro, Lara Maria Lopes de
Souza, Jacqueline de
Caldeira, Tamires Guedes
Mapa, Bruna de Carvalho
Soares, Anna Flávia Matos
Gomes, Bruna Pegorelli
Croce, Carolina Carvalho Della
Barcellos, Neila Marcia Silva
Palabras clave : Biopharmaceutics classification system
Fecha de publicación : 2020
Citación : CASTRO, L. M. L. et al. The evaluation of valsartan biopharmaceutics properties. Current Drug Research Reviews, v. 12, p. 1-11, 2020. Disponível em: <http://www.eurekaselect.com/177319/article>. Acesso em: 10 fev. 2020.
Resumen : Background: Solubility, intestinal permeability and dissolution are the main factors that govern the rate and extent of drugs absorption and are directly related to bioavailability. Biopharmaceutics Classification System (BCS) is an important tool that uses in vitro results for comparison with bioavailability in vivo (biowaiver). Valsartan is widely used in the treatment of hypertension and shows different BCS classification in the literature (BCS class II or III). Objective: This work proposes the study of valsartan biopharmaceutics properties and its BCS classification. Method: High performance liquid chromatography (HPLC) method was developed and validated to quantify the drug in buffers pH 1.2, 4.5 and 6.8. Valsartan solubility was determined in these three different media using shake flask method and intrinsic dissolution rate. Evaluation of dissolution profile from coated tablets was conducted. Results: The low solubility (pH 1.2 and 4.5) and high solubility (pH 6.8) was observed for both solubility methods. Permeability data reported from literature showed that valsartan is a low permeability drug. Valsartan presented rapid release profile only in pH 6.8. Conclusion: We defined that valsartan is a class IV drug, in disagreement with what has been published so far. It is important to emphasize that the conditions considered here are the indicated to define the biopharmaceutics classification by regulatory agencies.
URI : http://www.repositorio.ufop.br/handle/123456789/12242
metadata.dc.identifier.uri2: http://www.eurekaselect.com/177319/article
metadata.dc.identifier.doi: https://doi.org/10.2174/2589977511666191210151120
ISSN : 2589-9783
Aparece en las colecciones: DEFAR - Artigos publicados em periódicos

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
  Restricted Access
529,82 kBAdobe PDFVisualizar/Abrir

Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.